BACKGROUND: Solid tumors in general, and breast cancer in particular, depend on angiogenesis to grow and metastasize. Multiple agents have been developed in order to inhibit this phenomenon of tumor-induced angiogenesis. TNP-470 is one of the most potent of these drugs. We report here a case of regression of metastatic lesions from breast cancer due to the administration of the anti-angiogenic drug TNP-470. METHODS: A 44-year-old woman with a history of stage 2 breast cancer developed metastases at four sites: eye, lung, liver, and bone. She had been treated with radiation, megace, adriamycin, cytoxan, and 5-fluorouracil with disease stabilization. After she completed her radiation and chemotherapy, she was started on TNP-470. RESULTS: In response to TNP-470, her disease showed a partial response at the three-month follow-up and stabilization at the five-month follow-up. There were no side effects, and her quality of life was good. CONCLUSIONS: To our knowledge, this patient is the first reported case of regression of breast cancer metastases as a result of treatment with TNP-470. Anti-angiogenic drugs hold promise for the future therapy of breast cancer, and possibly of many other solid tumors as well.
BACKGROUND: Solid tumors in general, and breast cancer in particular, depend on angiogenesis to grow and metastasize. Multiple agents have been developed in order to inhibit this phenomenon of tumor-induced angiogenesis. TNP-470 is one of the most potent of these drugs. We report here a case of regression of metastatic lesions from breast cancer due to the administration of the anti-angiogenic drug TNP-470. METHODS: A 44-year-old woman with a history of stage 2 breast cancer developed metastases at four sites: eye, lung, liver, and bone. She had been treated with radiation, megace, adriamycin, cytoxan, and 5-fluorouracil with disease stabilization. After she completed her radiation and chemotherapy, she was started on TNP-470. RESULTS: In response to TNP-470, her disease showed a partial response at the three-month follow-up and stabilization at the five-month follow-up. There were no side effects, and her quality of life was good. CONCLUSIONS: To our knowledge, this patient is the first reported case of regression of breast cancer metastases as a result of treatment with TNP-470. Anti-angiogenic drugs hold promise for the future therapy of breast cancer, and possibly of many other solid tumors as well.
Authors: Dipanjan Pan; Shelton D Caruthers; Junjie Chen; Patrick M Winter; Angana SenPan; Anne H Schmieder; Samuel A Wickline; Gregory M Lanza Journal: Future Med Chem Date: 2010-03 Impact factor: 3.808
Authors: Dipanjan Pan; Nibedita Sanyal; Anne H Schmieder; Angana Senpan; Benjamin Kim; Xiaoxia Yang; Grace Hu; John S Allen; Richard W Gross; Samuel A Wickline; Gregory M Lanza Journal: Nanomedicine (Lond) Date: 2012-06-18 Impact factor: 5.307
Authors: G M Lanza; P M Winter; S D Caruthers; M S Hughes; Grace Hu; A H Schmieder; S A Wickline Journal: Angiogenesis Date: 2010-04-22 Impact factor: 9.596
Authors: Anne H Schmieder; Shelton D Caruthers; Huiying Zhang; Todd A Williams; J David Robertson; Samuel A Wickline; Gregory M Lanza Journal: FASEB J Date: 2008-08-12 Impact factor: 5.191
Authors: Patrick M Winter; Anne H Schmieder; Shelton D Caruthers; Jeffery L Keene; Huiying Zhang; Samuel A Wickline; Gregory M Lanza Journal: FASEB J Date: 2008-03-24 Impact factor: 5.191
Authors: Dipanjan Pan; Christine T N Pham; Katherine N Weilbaecher; Michael H Tomasson; Samuel A Wickline; Gregory M Lanza Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2015-08-21
Authors: Gregory M Lanza; John Jenkins; Anne H Schmieder; Aigul Moldobaeva; Grace Cui; Huiying Zhang; Xiaoxia Yang; Qiong Zhong; Jochen Keupp; Ismail Sergin; Krishna S Paranandi; Lindsey Eldridge; John S Allen; Todd Williams; Michael J Scott; Babak Razani; Elizabeth M Wagner Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556